SEC Comment Letter 0000000000-23-002955 to ASSEMBLY BIOSCIENCES, INC. (ASMB)
ASSEMBLY BIOSCIENCES, INC.
Date: March 24, 2023 · CIK: 0001426800 · Accession: 0000000000-23-002955
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270760
Letter
United States securities and exchange commission logo March 24, 2023 Jason Okazaki Chief Executive Officer Assembly Biosciences, Inc. 331 Oyster Point Blvd., Fourth Floor South San Francisco, CA 94080 Re:Assembly Biosciences, Inc. Registration Statement on Form S-3 Filed March 22, 2023 File No. 333-270760 Dear Jason Okazaki: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: P. Michelle Gasaway
Show Raw Text
United States securities and exchange commission logo
March 24, 2023
Jason Okazaki
Chief Executive Officer
Assembly Biosciences, Inc.
331 Oyster Point Blvd., Fourth Floor
South San Francisco, CA 94080
Re:Assembly Biosciences, Inc.
Registration Statement on Form S-3
Filed March 22, 2023
File No. 333-270760
Dear Jason Okazaki:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: P. Michelle Gasaway